Ruxolitinib Dosing for Anemic Myelofibrosis in an Older

home / case-based-peer-perspectives / ruxolitinib-dosing-for-anemic-myelofibrosis-in-an-older

Dr. Bose discusses the case of a 68-year-old woman with intermediate-2 risk myelofibrosis, including diagnostic findings, treatment selection based on guidelines, and goals of therapy. He reviews the impact of ruxolitinib on overall survival from the COMFORT trials and provides guidance on dosing, adverse effect management, and the role of emerging therapies. Dr. Bose also covers strategies for managing anemia in myelofibrosis patients on ruxolitinib. The REALISE trial implications for ruxolitinib dosing strategy are discussed.